Systems and methods for gas mixing in ocular surgical equipment
US-2019254870-A1 · Aug 22, 2019 · US
Methods of predicting ancestral virus sequences and uses thereof
US11466258B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11466258-B2 |
| Application number | US-202016906849-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 19, 2020 |
| Priority date | Oct 11, 2013 |
| Publication date | Oct 11, 2022 |
| Grant date | Oct 11, 2022 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Methods are described for predicting ancestral sequences for viruses or portions thereof. Also described are predicted ancestral sequences for adeno-associated virus (AAV) capsid polypeptides. The disclosure also provides methods of gene transfer and methods of vaccinating subjects by administering a target antigen operably linked to the AAV capsid polypeptides.
First claim
Opening claim text (preview).
What is claimed is: 1. An adeno-associated virus (AAV) capsid polypeptide having a variant of the amino acid sequence of SEQ ID NO: 23, wherein the variant has the amino acid sequence of SEQ ID NO:23 with at least one amino acid substitution selected from Arg168Lys, Ala205Ser, Gly266Ala, Lys311Arg, Gln411Glu, Thr460Glu, Thr493Ala, Asn562Ser, Glu576Gln, Ala587Ser, and Asp609Asn. 2. The AAV capsid polypeptide of claim 1 , having the variant of amino acid sequence of SEQ ID NO:23 with four amino acid substitutions, wherein the four substitutions are Lys311Arg, Gln411Glu, Thr493Ala, and Glu576Gln. 3. The AAV capsid polypeptide of claim 1 , having the variant of amino acid sequence of SEQ ID NO:23 with four amino acid substitutions, wherein the four substitutions are Arg168Lys, Ala205Ser, Thr460Glu, and Glu576Gln. 4. The AAV capsid polypeptide of claim 1 , having the variant of amino acid sequence of SEQ ID NO: 23 with four amino acid substitutions, wherein the four substitutions are Ala205Ser, Gln411Glu, Thr460Glu, and Asn562Ser. 5. The AAV capsid polypeptide of claim 1 , having the variant of amino acid sequence of SEQ ID NO: 23 with five amino acid substitutions, wherein the five substitutions are Lys311Arg, Gln411Glu, Thr460Glu, Asn562Ser, and Ala587Ser. 6. The AAV capsid polypeptide of claim 1 , having the variant of amino acid sequence of SEQ ID NO: 23 with six amino acid substitutions, wherein the six substitutions are Arg168Lys, Ala205Ser, Gly266Ala, Lys311Arg, Thr460Glu, and Asp609Asn. 7. The AAV capsid polypeptide of claim 1 , having the variant of amino acid sequence of SEQ ID NO:23 with seven amino acid substitutions, wherein the seven substitutions are Arg168Lys, Gln411Glu, Thr493Ala, Asn562Ser, Glu576Gln, Ala587Ser, and Asp609Asn. 8. The AAV capsid polypeptide of claim 1 , having the variant of amino acid sequence of SEQ ID NO:23 with seven amino acid substitutions, wherein the seven substitutions are Arg168Lys, Ala205Ser, Gln411Glu, Thr493Ala, Asn562Ser, Ala587Ser, and Asp609Asn. 9. The AAV capsid polypeptide of claim 1 , having the variant of amino acid sequence of SEQ ID NO: 23 with nine amino acid substitutions, wherein the nine substitutions are Arg168Lys, Gly266Ala, Lys311Arg, Gln411Glu, Thr493Ala, Asn562Ser, Glu576Gln, Ala587Ser, and Asp609Asn. 10. The AAV capsid polypeptide of claim 1 , wherein the AAV capsid polypeptide is purified. 11. A nucleic acid molecule encoding the AAV capsid polypeptide of claim 1 . 12. A vector comprising a nucleic acid molecule encoding the AAV capsid polypeptide of claim 1 . 13. An isolated host cell comprising a nucleic acid molecule encoding the AAV capsid polypeptide of claim 1 . 14. A purified virus particle comprising the AAV capsid polypeptide of claim 1 . 15. A pharmaceutical composition comprising a purified virus particle comprising the AAV capsid polypeptide of claim 1 in a pharmaceutically acceptable excipient.
Assignees
Inventors
Classifications
Viruses as such, e.g. new isolates, mutants or their genomic sequences · CPC title
- C12N7/00Primary
Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00) · CPC title
viral genome or elements thereof as genetic vector · CPC title
Viral vectors · CPC title
Use of virus, viral particle or viral elements as a vector · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11466258B2 cover?
- Methods are described for predicting ancestral sequences for viruses or portions thereof. Also described are predicted ancestral sequences for adeno-associated virus (AAV) capsid polypeptides. The disclosure also provides methods of gene transfer and methods of vaccinating subjects by administering a target antigen operably linked to the AAV capsid polypeptides.
- Who is the assignee on this patent?
- Massachusetts Eye & Ear Infirmary, Schepens Eye Res Inst
- What technology area does this patent fall under?
- Primary CPC classification C12N7/00. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Oct 11 2022 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 5 related publications on this page (citations in our corpus or others sharing the same primary CPC).